

# VERTEX PHARMACEUTICAL

ISIN: US92532F1003 WKN: 92532F100 Asset Class: **Stock**

## Company

2021/04/20 22:00:00



**Price**  
**220.16**  
USD

**Difference** 0.45%(0.98)



## Contact Details

VERTEX PHARMACEUTICALS,  
INC.

Tel: 1-617-341-6100

--

Fax: -

50 Northern Avenue

Web: <http://www.vrtx.com>

02210 Boston

E-mail:  
[mediainfo@vrtx.com](mailto:mediainfo@vrtx.com)

## Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2020		2019		2018	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	8,133,379,000		4,822,829,000		3,843,109,000	
<b>Common stock capital</b>		2,599,000		2,589,000		2,546,000
<b>Fixed assets</b>	3,618,429,000		3,495,636,000		2,402,789,000	
<b>Equity capital of a company</b>		8,686,815,000		6,085,244,000		4,435,203,000
<b>Cash and cash equivalents</b>	5,988,845,000		3,117,326,000		2,650,134,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		1,877,533,000		1,334,827,000		1,120,292,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		1,187,460,000		898,394,000		690,403,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		297,955,000		275,526,000		108,853,000
<b>Total assets</b>	11,751,808,000	11,751,808,000	8,318,465,000	8,318,465,000	6,245,898,000	6,245,898,000

## Balance notes

	2020	2019	2018
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	3,400	3,000	2,500
<b>Equity ratio</b>	73.92%	73.15%	71.01%
<b>Debt-equity ratio</b>	35.28%	36.70%	40.83%

## Others

	2020	2019	2018
<b>Tax Expense Rate</b>	13.00%	15.64%	-247.71%

# VERTEX PHARMACEUTICAL

ISIN: US92532F1003 WKN: 92532F100 Asset Class: Stock

## Income statement

	2020	2019	2018
Turnover	6,209,397,000	4,130,275,000	3,048,849,000
Net income	2,711,647,000	1,176,810,000	2,096,395,000
EBIT	2,634,719,747	1,161,408,225	530,134,652
Operating income before taxes	3,116,798,000	1,394,919,000	600,241,000
Cash Flow	3,253,505,000	1,569,330,000	1,270,286,000
Net interest income	-35,912,000	5,176,000	-34,119,000
Research and development expenses	1,829,537,000	1,754,540,000	1,416,476,000
Income taxes	405,151,000	218,109,000	-1,486,862,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,526,233	1,150,557	1,019,169

## Board of Directors

## Members of Management Board

Jeffrey Leiden	Chairman of Board of Directors
Alan Garber	Member of Board of Directors
Sangeeta Bhatia	Member of Board of Directors
Bruce Sachs	Member of Board of Directors
Diana McKenzie	Member of Board of Directors
Lloyd Carney	Member of Board of Directors
Margaret McGlynn	Member of Board of Directors
Terrence Kearney	Member of Board of Directors
Yuchun Lee	Member of Board of Directors
Reshma Kewalramani	Chairman of Managing Board
Bastiano Sanna	Member of Executive Committee
Carmen Bozic	Member of Executive Committee
David Altshuler	Member of Executive Committee
Nia Tatsis	Member of Executive Committee
Amit Sachdev	Member of Executive Committee
Charles Wagner	Member of Executive Committee
Damian Wilmot	Member of Executive Committee
Ludovic Fenaux	Member of Executive Committee
Michael Partridge	Member of Executive Committee
Mike Tirozzi	Member of Executive Committee